Tumor News and Research

RSS

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma is a devastating disease. There are roughly 20-25,000 new cases per year in the United States and it is increasing for some reason.

12 Feb 2013

New cancer research to be highlighted in AACR Annual Meeting 2013

The AACR Annual Meeting 2013 will bring more than 17,000 scientists, advocates, industry leaders and other professionals to Washington, D.C., for the latest in breakthrough cancer science.

12 Feb 2013

Researchers identify miR-506 as potential therapeutic candidate for metastatic ovarian cancer

Researchers employed an extensive analysis of genomic information to identify a new, high-risk cohort of ovarian cancer patients, characterize their tumors, find a potential treatment and test it in mouse models of the disease.

11 Feb 2013

Selumetinib shows high response rate for patients with low-grade serous ovarian cancer

Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, yet exceptionally difficult to treat when frontline therapy fails.

11 Feb 2013

MicroRNA can be used to define four subtypes of triple-negative breast cancer

A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy.

11 Feb 2013

Sunitinib does not cause lingering risks for cancer patients after their treatment ends

Studies in animals have raised concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued. But oncologists and physicists who collaborated to analyze data from the largest study of patients with kidney cancer convincingly demonstrate that such tumor acceleration does not occur in humans.

10 Feb 2013

SUVmax may help indicate progression-free survival in stage I NSCLC patients treated with SBRT

SUVmax (Maximum Standardized Uptake Value) may be a significant and clinically independent marker to indicate progression-free survival in stage I non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiation therapy (SBRT), according to research being presented at the 2013 Cancer Imaging and Radiation Therapy Symposium.

10 Feb 2013

Sunitinib shows promise against metastatic renal cell carcinoma

Findings from clinical trial patients with metastatic renal cell carcinoma, a common kidney cancer, show they did not have accelerated tumor growth after treatment with sunitinib, in contrast to some study results in animals. Sunitinib is one of several drugs, either on the market or undergoing testing, that target blood vessel growth.

10 Feb 2013

Combination of two antibodies prevents growth and spread of triple-negative breast tumors

Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are particularly aggressive and notoriously difficult to treat.

10 Feb 2013

Positive results from NCI-sponsored bevacizumab trial on cervical cancer

Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial.

10 Feb 2013

TGFβ inhibition enhances chemotherapy action against triple negative breast cancer

Due to chemotherapy resistance and a high rate of relapse, triple negative cancers are among the most difficult breast cancers to treat. In this issue of the Journal of Clinical Investigation, researchers led by Carlos Arteaga at Vanderbilt University identified a protein, TGF-β, that is highly expressed in triple negative breast cancer cells after chemotherapy.

10 Feb 2013

CtBP may play a key role in aggressive forms of breast cancer

A protein associated with conditions of metabolic imbalance, such as diabetes and obesity, may play a role in the development of aggressive forms of breast cancer, according to new findings by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and their colleagues.

9 Feb 2013

Scientists create nanoscale vehicle to battle cancer without harming healthy cells

A tiny capsule invented at a UCLA lab could go a long way toward improving cancer treatment. Devising a method for more precise and less invasive treatment of cancer tumors, a team led by researchers from the UCLA Henry Samueli School of Engineering and Applied Science has developed a degradable nanoscale shell to carry proteins to cancer cells and stunt the growth of tumors without damaging healthy cells.

9 Feb 2013

TIC10 may improve usefulness of TRAIL protein in cancer therapy

A compound that stimulates the production of a tumor-fighting protein may improve the usefulness of the protein in cancer therapy, according to a team of researchers.

9 Feb 2013

Etanercept no better than prednisone for COPD exacerbations

Results from a randomized, double-blind, controlled trial suggest that the tumor necrosis factor α antagonist etanercept is no more effective than standard therapy with prednisone for the treatment of acute exacerbations in patients with chronic obstructive pulmonary disease.

8 Feb 2013

Tumor necrosis factor receptor 2 involved in renal decline in diabetes

Researchers have found that circulating levels of tumor necrosis factor receptor 2 are independently associated with the development of chronic kidney disease in nonobese Japanese patients with Type 2 diabetes.

8 Feb 2013

Key details of how TRF2 protein performs crucial chromosome-protecting function

We take it for granted that our chromosomes won't stick together, yet this kind of cellular disaster would happen constantly were it not for a protein called TRF2. Now, scientists at The Scripps Research Institute (TSRI) have discovered key details of how TRF2 performs this crucial chromosome-protecting function.

7 Feb 2013

Tumor News and Research

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

New cancer research to be highlighted in AACR Annual Meeting 2013

Researchers identify miR-506 as potential therapeutic candidate for metastatic ovarian cancer

Selumetinib shows high response rate for patients with low-grade serous ovarian cancer

MicroRNA can be used to define four subtypes of triple-negative breast cancer

Sunitinib does not cause lingering risks for cancer patients after their treatment ends

SUVmax may help indicate progression-free survival in stage I NSCLC patients treated with SBRT

Sunitinib shows promise against metastatic renal cell carcinoma

Combination of two antibodies prevents growth and spread of triple-negative breast tumors

Positive results from NCI-sponsored bevacizumab trial on cervical cancer

TGFβ inhibition enhances chemotherapy action against triple negative breast cancer

CtBP may play a key role in aggressive forms of breast cancer

Scientists create nanoscale vehicle to battle cancer without harming healthy cells

TIC10 may improve usefulness of TRAIL protein in cancer therapy

Etanercept no better than prednisone for COPD exacerbations

Tumor necrosis factor receptor 2 involved in renal decline in diabetes

Key details of how TRF2 protein performs crucial chromosome-protecting function

Combination RT offers hope to late-stage esophageal cancer patients

Glimmer of hope for imatinib-resistant GIST

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News